Wednesday, July 8, 2026

pharma · Acne Rosacea · Atopic Dermatitis · DRMA

Dermata Therapeutics

Dermata Therapeutics is a pharma organization headquartered in San Diego, USA. It trades on NYSE under ticker DRMA. Primary therapeutic focus areas include Acne Rosacea, Atopic Dermatitis, Acne Vulgaris. NovaPharmaNews l

San Diego, USA HQ
2014 Founded
12 Employees
Public company Type
DRMA · NYSE Ticker
Company details
Status
Public
HQ
San Diego, USA
Founded
2014
Employees
12
Programs
4
Drugs
2
Patents
30
Clinical program

DMT210 Topical Gel

Phase 2 · small molecule · Atopic Dermatitis

DMT210 Topical Gel for Atopic Dermatitis is a Phase 2 program (small_molecule) at Dermata Therapeutics with 1 ClinicalTrials.gov record(s).

← All Dermata Therapeutics projects Phase 2 small molecule completed

Internal code DMT210-002

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Dermata Therapeutics
Phase
Phase 2
Modality
small_molecule
Indication
Atopic Dermatitis
Status
completed
Trials
1

Clinical trials